We read with great interest the study by Riedl et al.,1 which characterized acquired genetic resistance mechanisms to KRASG12C inhibitors (KRASG12Ci) across cancer types. While this comprehensive study offers valuable insights, it predominantly focused on colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC), with pancreatic ductal adenocarcinoma (PDAC) being significantly underrepresented. This knowledge gap has become increasingly important with the…
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
Annals of Oncology | | F. Castet, T.V. Tian, T. Macarulla
Topics: lung-cancer, colorectal-cancer, pancreatic-cancer, blood-cancer, cervical-cancer, research